yttrium-90-labeled murine anti-Tac

Yttrium-90-labeled murine anti-Tac is an investigational **CD25-directed radioimmunotherapy** developed at the National Cancer Institute for Tac-expressing adult T-cell leukemia/lymphoma and cutaneous T-cell lymphoma. It consists of the murine anti-Tac monoclonal antibody labeled with the beta-emitting isotope yttrium-90; antibody binding localizes radiation to malignant cells expressing interleukin-2 receptor alpha, causing radiation-mediated cytotoxicity. In an NCI Phase I/II adult T-cell leukemia study, 9 of 16 evaluable patients had partial or complete responses at 5-15 mCi doses. ([pubmed.ncbi.nlm.nih.gov](https://pubmed.ncbi.nlm.nih.gov/7492762/))

Other names

yttrium-90 anti-Tacyttrium90 anti-Tacyttrium 90 anti-Tacyttrium-90 radiolabeled anti-Tacyttrium90 radiolabeled anti-Tacyttrium 90 radiolabeled anti-Tac90Y anti-Tac